Exact Mass: 311.20158000000004
Exact Mass Matches: 311.20158000000004
Found 495 metabolites which its exact mass value is equals to given mass value 311.20158000000004,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Biperiden
A muscarinic antagonist that has effects in both the central and peripheral nervous systems. It has been used in the treatment of arteriosclerotic, idiopathic, and postencephalitic parkinsonism. It has also been used to alleviate extrapyramidal symptoms induced by phenothiazine derivatives and reserpine. [PubChem] D002491 - Central Nervous System Agents > D018726 - Anti-Dyskinesia Agents > D000978 - Antiparkinson Agents N - Nervous system > N04 - Anti-parkinson drugs > N04A - Anticholinergic agents > N04AA - Tertiary amines C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D010276 - Parasympatholytics D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018680 - Cholinergic Antagonists C78272 - Agent Affecting Nervous System > C38149 - Antiparkinsonian Agent Biperiden (KL 373) is a non-selective muscarinic receptor antagonist that competitively binds to M1 muscarinic receptors, thereby inhibiting acetylcholine and enhancing dopamine signaling in the central nervous system. Biperiden has the potential for the research of Parkinson's disease and other related psychiatric disorders[1][2].
Pretilachlor
CONFIDENCE standard compound; EAWAG_UCHEM_ID 3117
nalorphine
C19H21NO3 (311.15213560000007)
V - Various > V03 - All other therapeutic products > V03A - All other therapeutic products > V03AB - Antidotes D002492 - Central Nervous System Depressants > D009294 - Narcotics > D053610 - Opiate Alkaloids D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C78272 - Agent Affecting Nervous System > C67413 - Opioid Receptor Agonist D002491 - Central Nervous System Agents > D009292 - Narcotic Antagonists
(-)-Thebaine
C19H21NO3 (311.15213560000007)
D002491 - Central Nervous System Agents > D000697 - Central Nervous System Stimulants > D003292 - Convulsants D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D009294 - Narcotics D002492 - Central Nervous System Depressants > D009294 - Narcotics > D053610 - Opiate Alkaloids C78272 - Agent Affecting Nervous System > C67413 - Opioid Receptor Agonist > C1657 - Opiate D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D000700 - Analgesics (-)-Thebaine is a minor constituent of opiu
Machete
CONFIDENCE standard compound; INTERNAL_ID 560; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 10349; ORIGINAL_PRECURSOR_SCAN_NO 10345 CONFIDENCE standard compound; INTERNAL_ID 560; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 10330; ORIGINAL_PRECURSOR_SCAN_NO 10326 CONFIDENCE standard compound; INTERNAL_ID 560; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 10216; ORIGINAL_PRECURSOR_SCAN_NO 10211 CONFIDENCE standard compound; INTERNAL_ID 560; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 10284; ORIGINAL_PRECURSOR_SCAN_NO 10281 CONFIDENCE standard compound; INTERNAL_ID 560; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 10304; ORIGINAL_PRECURSOR_SCAN_NO 10299 CONFIDENCE standard compound; INTERNAL_ID 560; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 10247; ORIGINAL_PRECURSOR_SCAN_NO 10245 D010575 - Pesticides > D006540 - Herbicides D009676 - Noxae > D002273 - Carcinogens D016573 - Agrochemicals
Isothebaine
C19H21NO3 (311.15213560000007)
(R)-Pronuciferine
C19H21NO3 (311.15213560000007)
Alkaloid from Nelumbo nucifera (East India lotus). (R)-Pronuciferine is found in many foods, some of which are poppy, coffee and coffee products, sacred lotus, and cherimoya. (R)-Pronuciferine is found in cherimoya. (R)-Pronuciferine is an alkaloid from Nelumbo nucifera (East India lotus
17beta-Hydroxy-3-methoxyestra-1,3,5(10)-triene-17-carbonitrile
1-[(1R,4R)-5-bicyclo[2.2.1]hept-2-enyl]-1-phenyl-3-(1-piperidinyl)-1-propanol
N-[2-Methoxy-2-(4-methoxyphenyl)ethyl]cinnamide
C19H21NO3 (311.15213560000007)
N-[2-Methoxy-2-(4-methoxyphenyl)ethyl]cinnamide is found in fruits. N-[2-Methoxy-2-(4-methoxyphenyl)ethyl]cinnamide is isolated from Aegle marmelos (bael). Isolated from Aegle marmelos (bael). N-[2-Methoxy-2-(4-methoxyphenyl)ethyl]cinnamide is found in fruits.
Piperettine
C19H21NO3 (311.15213560000007)
Alkaloid from the dried fruits of Piper nigrum (pepper). Piperettine is found in herbs and spices and pepper (spice). Piperettine is found in herbs and spices. Piperettine is an alkaloid from the dried fruits of Piper nigrum (pepper
Lansamide 4
C19H21NO3 (311.15213560000007)
Lansamide 4 is found in fruits. Lansamide 4 is a constituent of Clausena lansium (wampee) Constituent of Clausena lansium (wampee). Lansamide 4 is found in fruits.
Arginylhistidine
Arginylhistidine is a dipeptide composed of arginine and histidine. It is an incomplete breakdown product of protein digestion or protein catabolism. Some dipeptides are known to have physiological or cell-signaling effects although most are simply short-lived intermediates on their way to specific amino acid degradation pathways following further proteolysis.
Histidylarginine
Histidylarginine is a dipeptide composed of histidine and arginine. It is an incomplete breakdown product of protein digestion or protein catabolism. Dipeptides are organic compounds containing a sequence of exactly two alpha-amino acids joined by a peptide bond. Some dipeptides are known to have physiological or cell-signalling effects although most are simply short-lived intermediates on their way to specific amino acid degradation pathways following further proteolysis.
2-trans,4-cis-Decadienoylcarnitine
2-trans,4-cis-Decadienoylcarnitine is an acylcarnitine. More specifically, it is an (2E,4Z)-deca-2,4-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 2-trans,4-cis-Decadienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 2-trans,4-cis-decadienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. In particular 2-trans,4-cis-decadienoylcarnitine is elevated in the blood or plasma of individuals with 2,4-dienoyl-coenzyme a reductase deficiency (PMID: 2332510, PMID: 15344554, PMID: 19578400). It is also decreased in the blood or plasma of individuals with familial mediterranean fever (PMID: 29900937) and schizophrenia (PMID: 31161852). Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews]. A human metabolite taken as a putative food compound of mammalian origin [HMDB]
Lansimide 3
C19H21NO3 (311.15213560000007)
Lansimide 3 is found in fruits. Lansimide 3 is a constituent of Clausena lansium (wampee)
(2E,4Z)-Decadienoylcarnitine
(2E,4Z)-Decadienoylcarnitine is an acylcarnitine. More specifically, it is an (2E,4Z)-decadienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (2E,4Z)-Decadienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (2E,4Z)-Decadienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. In particular (2E,4Z)-Decadienoylcarnitine is elevated in the blood or plasma of individuals with 2,4-dienoyl-coenzyme a reductase deficiency (PMID: 2332510, PMID: 15344554, PMID: 19578400). It is also decreased in the blood or plasma of individuals with familial mediterranean fever (PMID: 29900937) and schizophrenia (PMID: 31161852). Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(3,8)-Decadienoylcarnitine
(3,8)-Decadienoylcarnitine is an acylcarnitine. More specifically, it is an deca-3,8-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (3,8)-Decadienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (3,8)-Decadienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. In particular (3,8)-Decadienoylcarnitine is elevated in the blood or plasma of individuals with 2,4-dienoyl-coenzyme a reductase deficiency (PMID: 2332510, PMID: 15344554, PMID: 19578400). It is also decreased in the blood or plasma of individuals with familial mediterranean fever (PMID: 29900937) and schizophrenia (PMID: 31161852). Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(2,6)-Decadienoylcarnitine
(2,6)-Decadienoylcarnitine is an acylcarnitine. More specifically, it is an deca-2,6-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (2,6)-Decadienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (2,6)-Decadienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. In particular (2,6)-Decadienoylcarnitine is elevated in the blood or plasma of individuals with 2,4-dienoyl-coenzyme a reductase deficiency (PMID: 2332510, PMID: 15344554, PMID: 19578400). It is also decreased in the blood or plasma of individuals with familial mediterranean fever (PMID: 29900937) and schizophrenia (PMID: 31161852). Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(3,6)-Decadienoylcarnitine
(3,6)-Decadienoylcarnitine is an acylcarnitine. More specifically, it is an deca-3,6-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (3,6)-Decadienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (3,6)-Decadienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. In particular (3,6)-Decadienoylcarnitine is elevated in the blood or plasma of individuals with 2,4-dienoyl-coenzyme a reductase deficiency (PMID: 2332510, PMID: 15344554, PMID: 19578400). It is also decreased in the blood or plasma of individuals with familial mediterranean fever (PMID: 29900937) and schizophrenia (PMID: 31161852). Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(6,8)-Decadienoylcarnitine
(6,8)-Decadienoylcarnitine is an acylcarnitine. More specifically, it is an deca-6,8-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (6,8)-Decadienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (6,8)-Decadienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. In particular (6,8)-Decadienoylcarnitine is elevated in the blood or plasma of individuals with 2,4-dienoyl-coenzyme a reductase deficiency (PMID: 2332510, PMID: 15344554, PMID: 19578400). It is also decreased in the blood or plasma of individuals with familial mediterranean fever (PMID: 29900937) and schizophrenia (PMID: 31161852). Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(3,5)-Decadienoylcarnitine
(3,5)-Decadienoylcarnitine is an acylcarnitine. More specifically, it is an deca-3,5-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (3,5)-Decadienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (3,5)-Decadienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. In particular (3,5)-Decadienoylcarnitine is elevated in the blood or plasma of individuals with 2,4-dienoyl-coenzyme a reductase deficiency (PMID: 2332510, PMID: 15344554, PMID: 19578400). It is also decreased in the blood or plasma of individuals with familial mediterranean fever (PMID: 29900937) and schizophrenia (PMID: 31161852). Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(2,8)-Decadienoylcarnitine
(2,8)-Decadienoylcarnitine is an acylcarnitine. More specifically, it is an deca-2,8-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (2,8)-Decadienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (2,8)-Decadienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. In particular (2,8)-Decadienoylcarnitine is elevated in the blood or plasma of individuals with 2,4-dienoyl-coenzyme a reductase deficiency (PMID: 2332510, PMID: 15344554, PMID: 19578400). It is also decreased in the blood or plasma of individuals with familial mediterranean fever (PMID: 29900937) and schizophrenia (PMID: 31161852). Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(4,6)-Decadienoylcarnitine
(4,6)-Decadienoylcarnitine is an acylcarnitine. More specifically, it is an deca-4,6-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (4,6)-Decadienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (4,6)-Decadienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. In particular (4,6)-Decadienoylcarnitine is elevated in the blood or plasma of individuals with 2,4-dienoyl-coenzyme a reductase deficiency (PMID: 2332510, PMID: 15344554, PMID: 19578400). It is also decreased in the blood or plasma of individuals with familial mediterranean fever (PMID: 29900937) and schizophrenia (PMID: 31161852). Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(5,8)-Decadienoylcarnitine
(5,8)-Decadienoylcarnitine is an acylcarnitine. More specifically, it is an deca-5,8-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (5,8)-Decadienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (5,8)-Decadienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. In particular (5,8)-Decadienoylcarnitine is elevated in the blood or plasma of individuals with 2,4-dienoyl-coenzyme a reductase deficiency (PMID: 2332510, PMID: 15344554, PMID: 19578400). It is also decreased in the blood or plasma of individuals with familial mediterranean fever (PMID: 29900937) and schizophrenia (PMID: 31161852). Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(2,7)-Decadienoylcarnitine
(2,7)-Decadienoylcarnitine is an acylcarnitine. More specifically, it is an deca-2,7-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (2,7)-Decadienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (2,7)-Decadienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. In particular (2,7)-Decadienoylcarnitine is elevated in the blood or plasma of individuals with 2,4-dienoyl-coenzyme a reductase deficiency (PMID: 2332510, PMID: 15344554, PMID: 19578400). It is also decreased in the blood or plasma of individuals with familial mediterranean fever (PMID: 29900937) and schizophrenia (PMID: 31161852). Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(4,7)-Decadienoylcarnitine
(4,7)-Decadienoylcarnitine is an acylcarnitine. More specifically, it is an deca-4,7-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (4,7)-Decadienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (4,7)-Decadienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. In particular (4,7)-Decadienoylcarnitine is elevated in the blood or plasma of individuals with 2,4-dienoyl-coenzyme a reductase deficiency (PMID: 2332510, PMID: 15344554, PMID: 19578400). It is also decreased in the blood or plasma of individuals with familial mediterranean fever (PMID: 29900937) and schizophrenia (PMID: 31161852). Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(5,7)-Decadienoylcarnitine
(5,7)-Decadienoylcarnitine is an acylcarnitine. More specifically, it is an deca-5,7-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (5,7)-Decadienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (5,7)-Decadienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. In particular (5,7)-Decadienoylcarnitine is elevated in the blood or plasma of individuals with 2,4-dienoyl-coenzyme a reductase deficiency (PMID: 2332510, PMID: 15344554, PMID: 19578400). It is also decreased in the blood or plasma of individuals with familial mediterranean fever (PMID: 29900937) and schizophrenia (PMID: 31161852). Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(4,8)-Decadienoylcarnitine
(4,8)-Decadienoylcarnitine is an acylcarnitine. More specifically, it is an deca-4,8-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (4,8)-Decadienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (4,8)-Decadienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. In particular (4,8)-Decadienoylcarnitine is elevated in the blood or plasma of individuals with 2,4-dienoyl-coenzyme a reductase deficiency (PMID: 2332510, PMID: 15344554, PMID: 19578400). It is also decreased in the blood or plasma of individuals with familial mediterranean fever (PMID: 29900937) and schizophrenia (PMID: 31161852). Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(3,7)-Decadienoylcarnitine
(3,7)-Decadienoylcarnitine is an acylcarnitine. More specifically, it is an deca-3,7-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (3,7)-Decadienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (3,7)-Decadienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. In particular (3,7)-Decadienoylcarnitine is elevated in the blood or plasma of individuals with 2,4-dienoyl-coenzyme a reductase deficiency (PMID: 2332510, PMID: 15344554, PMID: 19578400). It is also decreased in the blood or plasma of individuals with familial mediterranean fever (PMID: 29900937) and schizophrenia (PMID: 31161852). Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(2,5)-Decadienoylcarnitine
(2,5)-Decadienoylcarnitine is an acylcarnitine. More specifically, it is an deca-2,5-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (2,5)-Decadienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (2,5)-Decadienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. In particular (2,5)-Decadienoylcarnitine is elevated in the blood or plasma of individuals with 2,4-dienoyl-coenzyme a reductase deficiency (PMID: 2332510, PMID: 15344554, PMID: 19578400). It is also decreased in the blood or plasma of individuals with familial mediterranean fever (PMID: 29900937) and schizophrenia (PMID: 31161852). Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(1-Pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone
1-(1-Pentyl-1h-indol-3-yl)-3-methyl-2-(propan-2-yl)but-3-en-1-one
3-(((4,7-Dimethyl-1,3-benzoxazol-2-yl)methyl)amino)-5-ethyl-6-methylpyridin-2(1H)-one
Vephylline
C13H21N5O4 (311.15934660000005)
Butofilolol
C17H26FNO3 (311.18966180000007)
Dienogest
Lethidrone
C19H21NO3 (311.15213560000007)
D002492 - Central Nervous System Depressants > D009294 - Narcotics > D053610 - Opiate Alkaloids D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D009292 - Narcotic Antagonists
Noberastine
C308 - Immunotherapeutic Agent > C29578 - Histamine-1 Receptor Antagonist
Xanthinol
C13H21N5O4 (311.15934660000005)
(9S,10E,12Z)-9-hydroperoxy-10,12-octadecadienoate
(9s,10e,12z)-9-hydroperoxy-10,12-octadecadienoate, also known as 9(S)-hydroperoxy-10(E),12(z)-octadecadienoic acid or 9(S)-hpod(1-), belongs to lineolic acids and derivatives class of compounds. Those are derivatives of lineolic acid. Lineolic acid is a polyunsaturated omega-6 18 carbon long fatty acid, with two CC double bonds at the 9- and 12-positions (9s,10e,12z)-9-hydroperoxy-10,12-octadecadienoate is practically insoluble (in water) and a weakly acidic compound (based on its pKa). (9s,10e,12z)-9-hydroperoxy-10,12-octadecadienoate can be found in a number of food items such as mexican groundcherry, brazil nut, coconut, and winter savory, which makes (9s,10e,12z)-9-hydroperoxy-10,12-octadecadienoate a potential biomarker for the consumption of these food products.
Dienogest
G - Genito urinary system and sex hormones > G03 - Sex hormones and modulators of the genital system > G03D - Progestogens > G03DB - Pregnadien derivatives C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C1636 - Therapeutic Steroid Hormone D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006728 - Hormones D012102 - Reproductive Control Agents > D003270 - Contraceptive Agents D000970 - Antineoplastic Agents CONFIDENCE standard compound; EAWAG_UCHEM_ID 3284
(1Z)-4-Isopropyl-1-(2-methylpropylidene)-2H-pyrazino[2,1-b]quinazoline-3,6(1H,4H)-dione
adiphenine
C78272 - Agent Affecting Nervous System > C29698 - Antispasmodic Agent
N-Tetradecanoyl-DL-homoserine lactone
C18H33NO3 (311.24603079999997)
(-)-beta-8-methylpseudoanibacanine|(8S,13aS)-form-8-Methylpseudoanibacanine
C19H21NO3 (311.15213560000007)
1,10-dimethoxy-6-methyl-aporphan-11-ol|isothebaine
C19H21NO3 (311.15213560000007)
(-)-2-Hydroxy-3,8-dimethoxypavinane
C19H21NO3 (311.15213560000007)
15,16-methanediyldioxy-3alpha-methoxy-11a-homo-erythrina-1,6-diene|Schelhammeridin|Schelhammeridine
C19H21NO3 (311.15213560000007)
2-Methylbutyric acid 2-[(2-hydroxyethyl)amino]-1,5-dimethyl-4-methoxy-6-oxo-2,4-cyclohexadien-1-yl ester
1-methyl-2-(3-hydroxy-3,7-dimethyl-octa-1,6-dienyl)quinolin-4(1h)-one
2-[2-(3,4-dimethoxyphenyl)ethyl]-1-methyl-3,4-dihydro-2H-quinoline
seco-pseudopteroxazole
A natural product found in Pseudopterogorgia elisabethae.
(S)-3-((2-(2-methylbut-3-en-2-yl)-1H-indol-3-yl)methyl)piperazine-2,5-dione|talathermophilin E
1-methyl-2-[(E)-1-undecenyl]-4(1H)-quinolone|1-methyl-2-[(E)-1-undecenyl]-4(1H)-quinolone
(+/-)-1-hydroxy-2,9-dimethoxyaporphine|2,9-dimethoxy-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-1-ol|dl-Lirinine|Lirinin|Orientinine
C19H21NO3 (311.15213560000007)
15,16-ethane-1,2-diyldioxy-3beta-methoxy-erythrina-1,6-diene|Erythralin
C19H21NO3 (311.15213560000007)
(-)-alpha-8-methylanibacanine|(8R,13aS)-form-8-Methylanibacanine
C19H21NO3 (311.15213560000007)
thebaine
C19H21NO3 (311.15213560000007)
D002491 - Central Nervous System Agents > D000697 - Central Nervous System Stimulants > D003292 - Convulsants D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D009294 - Narcotics D002492 - Central Nervous System Depressants > D009294 - Narcotics > D053610 - Opiate Alkaloids C78272 - Agent Affecting Nervous System > C67413 - Opioid Receptor Agonist > C1657 - Opiate D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D000700 - Analgesics relative retention time with respect to 9-anthracene Carboxylic Acid is 0.549 relative retention time with respect to 9-anthracene Carboxylic Acid is 0.537 IPB_RECORD: 2881; CONFIDENCE confident structure
C21H29NO_1-Methyl-2-[(6Z)-6-undecen-1-yl]-4(1H)-quinolinone
C18H21N3O2_(1Z)-4-Isopropyl-1-(2-methylpropylidene)-2H-pyrazino[2,1-b]quinazoline-3,6(1H,4H)-dione
1-(2-methylpropylidene)-4-(propan-2-yl)-1H,2H,3H,4H,6H-piperazino[2,1-b]quinazoline-3,6-dione
(1-Pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone
C14-homoserine lactone
C18H33NO3 (311.24603079999997)
CONFIDENCE standard compound; INTERNAL_ID 206
biperiden
D002491 - Central Nervous System Agents > D018726 - Anti-Dyskinesia Agents > D000978 - Antiparkinson Agents N - Nervous system > N04 - Anti-parkinson drugs > N04A - Anticholinergic agents > N04AA - Tertiary amines C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D010276 - Parasympatholytics D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018680 - Cholinergic Antagonists C78272 - Agent Affecting Nervous System > C38149 - Antiparkinsonian Agent Biperiden (KL 373) is a non-selective muscarinic receptor antagonist that competitively binds to M1 muscarinic receptors, thereby inhibiting acetylcholine and enhancing dopamine signaling in the central nervous system. Biperiden has the potential for the research of Parkinson's disease and other related psychiatric disorders[1][2].
deoxycommendamide (putative) or in source fragment -H2O observed in AGP sample
C18H33NO3 (311.24603079999997)
(dehydrohexadecanoyl)glycine - Commendamide analogue
C18H33NO3 (311.24603079999997)
Pretilachlor
Precursor ion is [M+H]+ of 37Cl-containing molecule.; The sample was injected by direct infusion.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 19HP8024 to the Mass Spectrometry Society of Japan. The sample was injected by direct infusion.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 19HP8024 to the Mass Spectrometry Society of Japan.
17-hydroxy-3-oxo-, (17??)-19-Norpregna-5(10),9(11)-diene-21-nitrile
(7R,8R,E)-6-((2R)-7-hydroxy-2,6-dimethylheptylidene)-8-methyloctahydroindolizine-7,8-diol
C18H33NO3 (311.24603079999997)
(-)-Thebaine
C19H21NO3 (311.15213560000007)
Lansimide 3
C19H21NO3 (311.15213560000007)
Piperettine
C19H21NO3 (311.15213560000007)
Lansamide 4
C19H21NO3 (311.15213560000007)
A 3-hydroxy-6-methoxy-1-methyl-4,5-diphenyl-2-piperidinone in which positions 3,4,5 and 6 have S,S,R,R stereochemistry, respectively.
Aegle marmelos alkaloid D
C19H21NO3 (311.15213560000007)
CAR 10:2
3-(Dimethylamino)-1,2-bis(4-methoxyphenyl)-2-propen-1-one
C19H21NO3 (311.15213560000007)
Alphamethadol
D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D009294 - Narcotics D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C78272 - Agent Affecting Nervous System > C67413 - Opioid Receptor Agonist D002491 - Central Nervous System Agents > D000700 - Analgesics C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent
N,N-dimethyl-1-spiro[1,3-dioxolane-2,11-6H-benzo[c][1]benzoxepine]-4-ylmethanamine
C19H21NO3 (311.15213560000007)
Butofilolol
C17H26FNO3 (311.18966180000007)
C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists
2-[(1-ADAMANTYLCARBONYL)AMINO]-4-(METHYLTHIO)BUTANOIC ACID
C16H25NO3S (311.15550600000006)
tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)piperidine-1-carboxylate
2-(3-(tert-butoxycarbonyl)-3-azaspiro[5.5]undecane-9-yl)acetic acid
(1R, 2R)-Pseudoephedrine-(S)-2-methylhydrocinnamamide
(4-(5-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PYRIDIN-3-YL)PHENYL)METHANOL
C18H22BNO3 (311.16926520000004)
Piperazine, 2-Methyl-4-(4-nitrophenyl)-1-(phenylmethyl)-, (2R)-
N-(3-methoxyphenyl)-2-[4-(2-methylpropyl)phenyl]propanamide
buta-1,3-diene,methyl 2-methylprop-2-enoate,prop-2-enenitrile,styrene
(S)-(-)N-CARBOMETHOXY-ALPHA,ALPHA-DIPHENYL-2-PYRROLIDINEMETHANOL,98
C19H21NO3 (311.15213560000007)
(2R,4S)-ethyl 5-([1,1-biphenyl]-4-yl)-4-amino-2-Methylpentanoate
3,5-DICHLOROBENZENE-1-CARBOXIMIDAMIDEHYDROCHLORIDE
Benzyldimethyldecylammonium chloride purum,
C19H34ClN (311.23796340000007)
Talsupram
C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C185721 - Norepinephrine Reuptake Inhibitor C78272 - Agent Affecting Nervous System > C265 - Antidepressant Agent
3-[(3-methoxyphenyl)methyl]-7,7-dimethyl-6,8-dihydro-1H-quinoline-2,5-dione
C19H21NO3 (311.15213560000007)
(2,4,6-trimethylphenyl)methyl 2-benzamidoacetate
C19H21NO3 (311.15213560000007)
N-BENZYL-5-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PYRIMIDIN-2-AMINE
5-(4-Methoxyphenyl)-3-methyl-1-oxa-3-azaspiro[5.5]undecane hydroc hloride
1-ethenylpyrrolidin-2-one,ethyl 2-methylprop-2-enoate,2-methylprop-2-enoic acid
Femoxetine
D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D017367 - Selective Serotonin Reuptake Inhibitors D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D000928 - Antidepressive Agents D018377 - Neurotransmitter Agents > D014179 - Neurotransmitter Uptake Inhibitors C78272 - Agent Affecting Nervous System > C47794 - Serotonin Agonist D049990 - Membrane Transport Modulators D000890 - Anti-Infective Agents
1-BENZYL-4-(4,4,5,5-TETRAMETHYL-[1,3,2]DIOXABOROLAN-2-YL)-1H-PYRIDIN-2-ONE
C18H22BNO3 (311.16926520000004)
N-[(2R)-3-[[3-Fluoro-4-(4-morpholinyl)phenyl]amino]-2-hydroxypropyl]acetamide
C15H22FN3O3 (311.16451140000004)
Fomocaine
C78272 - Agent Affecting Nervous System > C245 - Anesthetic Agent
ETHYL 2-METHYL-5-OXO-4-PHENYL-1,4,5,6,7,8-HEXAHYDRO-3-QUINOLINECARBOXYLATE
C19H21NO3 (311.15213560000007)
Acetamide,N-(2-chlorophenyl)-2-[[2-(diethylamino)ethyl]ethylamino]-
2-(BENZYLOXY)-4-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PYRIDINE
C18H22BNO3 (311.16926520000004)
6-Benzyloxypyridine-3-boronic acid pinacol ester
C18H22BNO3 (311.16926520000004)
1-(6,7-DIMETHOXY-1-PHENYL-3,4-DIHYDRO-1H-ISOQUINOLIN-2-YL)-ETHANONE
C19H21NO3 (311.15213560000007)
(S)-Di-tert-butyl2-cyanopiperazine-1,4-dicarboxylate
Ethyl 3-(dibenzylamino)-2-oxopropanoate
C19H21NO3 (311.15213560000007)
3-AMINO-N,N-DIETHYL-4-PIPERIDIN-1-YL-BENZENESULFONAMIDE
Butanoic acid, 4-[bis(phenylmethyl)amino]-, ethyl ester
(2S)-1-Amino-3-{[3-fluoro-4-(4-morpholinyl)phenyl]amino}-2-propanyl acetate
C15H22FN3O3 (311.16451140000004)
(R)-(+)-N-CARBOMETHOXY-ALPHA, ALPHA-DIPHEN YL-2-PYRROLIDINEMETHANOL
C19H21NO3 (311.15213560000007)
1-{4-[(2-Ethoxyethoxy)methyl]phenoxy}-3-(isopropylamino)-2-propanol
1-Benzylpyridin-2(1H)-one-5-boronic acid pinacol ester
C18H22BNO3 (311.16926520000004)
Benzenamine, 5-chloro-2-(dodecyloxy)-
C18H30ClNO (311.20158000000004)
3-Oxobutanoic acid 2-[phenyl(phenylmethyl)amino]ethyl ester
C19H21NO3 (311.15213560000007)
trans-1-(tert-butoxycarbonyl)-4-(cyclohexylmethyl)pyrrolidine-3-carboxylic acid
N-(furan-2-ylmethyl)-1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methanimine
C18H22BNO3 (311.16926520000004)
3-Pyrrolidinecarboxylic acid, 4-(3-methoxyphenyl)-1-(phenylmethyl)-
C19H21NO3 (311.15213560000007)
2-Benzyloxypyridine-3-boronic acid pinacol ester
C18H22BNO3 (311.16926520000004)
2-Methoxyoestra-1,3,5(10),16-tetraene-3-carboxamide
Benzoic acid, p-hydroxy-, (p-(diethylamino)benzylidene)hydrazide
Val-pro-pro
D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D000806 - Angiotensin-Converting Enzyme Inhibitors A tripeptide composed of L-valine and two L-proline units joined by peptide linkages. H-Val-Pro-Pro-OH, a milk-derived proline peptides derivative, is an inhibitor of Angiotensin I converting enzyme (ACE), with an IC50 of 9 μM. H-Val-Pro-Pro-OH, a milk-derived proline peptides derivative, is an inhibitor of Angiotensin I converting enzyme (ACE), with an IC50 of 9 μM. H-Val-Pro-Pro-OH, a milk-derived proline peptides derivative, is an inhibitor of Angiotensin I converting enzyme (ACE), with an IC50 of 9 μM.
Ambutonium
C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent
(R)-6-Propyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-2,10,11-triol
C19H21NO3 (311.15213560000007)
N-[2-(2-methoxyphenoxy)ethyl]-2,3-dihydro-1H-indene-5-carboxamide
C19H21NO3 (311.15213560000007)
N-{(E)-[4-(dimethylamino)phenyl]methylidene}-2-(3-methylphenoxy)acetohydrazide
1-phenyl-N-(3-propan-2-yloxypropyl)-4-pyrazolo[3,4-d]pyrimidinamine
1,7,7-Trimethyl-4-[(2-methyl-2,3-dihydroindol-1-yl)-oxomethyl]-2-bicyclo[2.2.1]heptanone
N-[2-(3,4-Dimethoxy-phenyl)-ethyl]-3-phenyl-acrylamide
C19H21NO3 (311.15213560000007)
(S)-3-Oxo-N-(2-oxotetrahydrofuran-3-yl)tridecanamide
(2s)-2-{[3-(3-Aminophenyl)imidazo[1,2-B]pyridazin-6-Yl]amino}-3-Methylbutan-1-Ol
Butanex
D010575 - Pesticides > D006540 - Herbicides D009676 - Noxae > D002273 - Carcinogens D016573 - Agrochemicals
13(S)-Hpode(1-)
Conjugate base of 13(S)-HPODE arising from deprotonation of the carboxylic acid function.
(11S)-11-Hydroperoxylinoleate
Conjugate base of (11S)-11-hydroperoxylinoleic acid arising from deprotonation of the carboxylic acid function.
5(S),8(R)-DiHODE(1-)
A monocarboxylic acid anion resulting from the deprotonation of the carboxy group of 5(S),8(R)-DiHODE. The major species at pH 7.3.
(8E,10R,12Z)-10-Hydroperoxy-8,12-octadecadienoate
The hydroperoxy fatty acid anion that is the conjugate base of hydroperoxy fatty acid anion, formed by deprotonation of the carboxy group; principal microspecies at pH 7.3.
(8E,10S,12Z)-10-hydroperoxyoctadeca-8,12-dienoate
An unsaturated fatty acid anion that is the conjugate base of (8E,10S,12Z)-10-hydroperoxyoctadeca-8,12-dienoic acid, obtained by deprotonation of the carboxy group.
(12Z,15Z)-9,10-dihydroxyoctadeca-12,15-dienoic acid
8-[3-[(3-Pentyloxiran-2-yl)methyl]oxiran-2-yl]octanoate
(7S,8S,9Z,12Z)-7,8-dihydroxy-9,12-octadecadienoate
1-(4-Morpholinyl)-2-(4-phenylphenoxy)-1-propanone
C19H21NO3 (311.15213560000007)
N-[(3R)-1-azabicyclo[2.2.2]octan-3-yl]-2-(1-methyl-3-indolyl)-2-oxoacetamide
13-HPODE(1-)
A hydroperoxy fatty acid anion that is the conjugate base of 13-HPODE arising from deprotonation of the carboxylic acid function; major species at pH 7.3.
N-[2-(2-fluorophenyl)ethyl]-5,6,7,8-tetrahydro-[1,2,4]triazolo[5,1-b]quinazolin-9-amine
C17H18FN5 (311.15461600000003)
3-(((4-(2-Methoxyphenyl)-1-piperazinyl)imino)methyl)phenol
6-ethyl-N-[2-(4-methoxyphenyl)ethyl]-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine
2-Methoxy-6-[[(1-propyl-5-benzimidazolyl)amino]methyl]phenol
7(S),8(S)-DiHODE(1-)
Conjugate base of 7(S),8(S)-DiHODE arising from deprotonation of the carboxylic acid function.
N-[4-[[(3,4-dimethylanilino)-oxomethyl]amino]phenyl]-N-methylacetamide
1-(1-Methylcyclopentyl)-1-phenyl-4-(1-piperidinyl)-2-butyn-1-ol
4-(dimethylamino)-N-[1-(3-methoxyphenyl)ethylidene]benzohydrazide
3-(4-Ethyl-1-piperazinyl)-5-methylpyridazino[3,4-b][1,4]benzoxazine
11-hydroxy-(12S,13S)-epoxy-(9Z)-octadecenoate(1-)
A monounsaturated fatty acid anion that is the conjugate base of 11-hydroxy-(12S,13S)-epoxy-(9Z)-octadecenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.
2-[(E)-[4-(Dimethylamino)phenyl]methylideneamino]oxy-N-(4-methylphenyl)acetamide
8-{3-[(2Z)-8-hydroxyoct-2-en-1-yl]oxiran-2-yl}octanoate
(9Z)-11-[3-(5-hydroxypentyl)oxiran-2-yl]undec-9-enoate
4-(4-phenylmethoxyphenoxy)-N-prop-2-enyl-1-butanamine
Ibogaine(1+)
A tertiary ammonium ion resulting from the protonation of the tertiary amino group of ibogaine.
1-[(1S,4S)-2-bicyclo[2.2.1]hept-5-enyl]-1-phenyl-3-piperidin-1-ylpropan-1-ol
(4S)-4-[(2E,4Z)-2,4-Decadienoyloxy]-4-(trimethylammonio)butanoate
1-[(2S,3R,6S)-6-(2-aminoethyl)-2-(hydroxymethyl)-3-oxanyl]-3-(4-fluorophenyl)urea
C15H22FN3O3 (311.16451140000004)
1-[(2R,3S,6S)-6-(2-aminoethyl)-2-(hydroxymethyl)-3-oxanyl]-3-(4-fluorophenyl)urea
C15H22FN3O3 (311.16451140000004)
1-[(2R,3R,6S)-6-(2-aminoethyl)-2-(hydroxymethyl)-3-oxanyl]-3-(4-fluorophenyl)urea
C15H22FN3O3 (311.16451140000004)
1-[(2R,3S,6R)-6-(2-aminoethyl)-2-(hydroxymethyl)-3-oxanyl]-3-(4-fluorophenyl)urea
C15H22FN3O3 (311.16451140000004)
1-[(2R,3R,6R)-6-(2-aminoethyl)-2-(hydroxymethyl)-3-oxanyl]-3-(4-fluorophenyl)urea
C15H22FN3O3 (311.16451140000004)
1-[(2S,3R,6R)-6-(2-aminoethyl)-2-(hydroxymethyl)-3-oxanyl]-3-(4-fluorophenyl)urea
C15H22FN3O3 (311.16451140000004)
1-[(2S,3S,6S)-6-(2-aminoethyl)-2-(hydroxymethyl)-3-oxanyl]-3-(4-fluorophenyl)urea
C15H22FN3O3 (311.16451140000004)
1-[(2S,3S,6R)-6-(2-aminoethyl)-2-(hydroxymethyl)-3-oxanyl]-3-(4-fluorophenyl)urea
C15H22FN3O3 (311.16451140000004)
(dehydrohexadecanoyl)glycine-Commendamide analogue
C18H33NO3 (311.24603079999997)
(3S,4S,5R,6R)-3-hydroxy-6-methoxy-1-methyl-4,5-diphenylpiperidin-2-one
C19H21NO3 (311.15213560000007)
(2S)-2-Amino-N-(2,6-dimethylphenyl)-N-[3-(3-pyridinyl)propyl]propanamide
1-(4-Fluorophenyl)-2-phenyl-3-(1-piperidinyl)-1-propanone
N-ethyl-N-(3-methylphenyl)-N-(7H-purin-1-ium-6-yl)propane-1,3-diamine
(3S)-3-[(2E,4Z)-deca-2,4-dienoyl]oxy-4-(trimethylazaniumyl)butanoate
2-[(8S,13R,14S,17R)-17-hydroxy-13-methyl-3-oxo-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-17-yl]acetonitrile
N-[(4E,8E)-1,3-dihydroxypentadeca-4,8-dien-2-yl]propanamide
C18H33NO3 (311.24603079999997)
N-[(4E,8E)-1,3-dihydroxyhexadeca-4,8-dien-2-yl]acetamide
C18H33NO3 (311.24603079999997)
N-[(4E,8E)-1,3-dihydroxytrideca-4,8-dien-2-yl]pentanamide
C18H33NO3 (311.24603079999997)
N-[(4E,8E)-1,3-dihydroxytetradeca-4,8-dien-2-yl]butanamide
C18H33NO3 (311.24603079999997)
N-[(4E,8E)-1,3-dihydroxydodeca-4,8-dien-2-yl]hexanamide
C18H33NO3 (311.24603079999997)
3-(1,3,6-Trimethyl-3-piperiden-4-yl)-2-(2-methyl-2-aminopropyl)indole
(+)-Pronuciferine
C19H21NO3 (311.15213560000007)
An isoquinoline alkaloid isolated from Berberis coletioides.
Butachlore
D010575 - Pesticides > D006540 - Herbicides D009676 - Noxae > D002273 - Carcinogens D016573 - Agrochemicals
9(S)-HPODE(1-)
A monocarboxylic acid anion obtained by removal of a proton from the carboxylic acid group of 9(S)-HPODE.
8(R)-HPODE(1-)
A monocarboxylic acid anion resulting from the deprotonation of the carboxy group of 8(R)-HPODE. The major species at pH 7.3.
9(R)-HPODE(1-)
A monocarboxylic acid anion obtained by removal of a proton from the carboxylic acid group of 9(R)-HPODE.
13(R)-HPODE(1-)
A 13-HPODE(1-) that is the conjugate base of 13(R)-HPODE, obtained by deprotonation of the carboxylic acid function. Major microspecies at pH 7.3.
(2E,4Z)-decadienoylcarnitine
An O-acylcarnitine having (2E,4Z)-decadienoyl as the acyl substituent.
3-Hydroxy-6-methoxy-1-methyl-4,5-diphenyl-2-piperidinone
C19H21NO3 (311.15213560000007)
A member of the class of piperidones that is 1-methylpiperidin-2-one in which a hydrogen at positions 3,4,5 and 6 has been replaced by hydroxy, phenyl, phenyl and methoxy groups, respectively.
N-(2-oxooxolan-3-yl)tetradecanamide
C18H33NO3 (311.24603079999997)
(8R)-7-propyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-2,13,14-triol
C19H21NO3 (311.15213560000007)
N-[(9Z)-hexadecenoyl]glycine
C18H33NO3 (311.24603079999997)
A fatty acid amide resulting from the formal condensation of the carboxy group of (9Z)-hexadecenoic acid with the amino group of glycine.
O-decadienoylcarnitine
An O-acylcarnitine in which the acyl group specified is decadienoyl in which the positions of the double bonds is unspecified..
O-decadienoyl-L-carnitine
An O-acyl-L-carnitine that is L-carnitine having decadienoyl group as the acyl substituent in which the positions of the two double bonds are unspecified.
(12s,15r,16s,17r)-11,11,15-trimethyl-10,19-dioxa-2-azapentacyclo[14.2.1.0³,⁸.0⁹,¹⁸.0¹²,¹⁷]nonadeca-1,3,5,7,9(18)-pentaen-15-ol
C19H21NO3 (311.15213560000007)
(12br)-10,11-dimethoxy-7,8,12b,13-tetrahydro-5h-6-azatetraphen-2-ol
C19H21NO3 (311.15213560000007)
2-[(2e)-1-hydroxy-3,7-dimethylocta-2,6-dien-1-yl]-1-methylquinolin-4-one
(1r)-2-[(2-hydroxyethyl)amino]-4-methoxy-1,5-dimethyl-6-oxocyclohexa-2,4-dien-1-yl (2r)-2-methylbutanoate
(5s,12bs)-10-methoxy-5-methyl-7,8,12b,13-tetrahydro-5h-6-azatetraphene-2,11-diol
C19H21NO3 (311.15213560000007)
3,15-dimethoxy-10-methyl-10-azatetracyclo[7.7.1.0²,⁷.0¹³,¹⁷]heptadeca-1(16),2(7),3,5,13(17),14-hexaen-16-ol
C19H21NO3 (311.15213560000007)
(6s)-6-hydroxy-5-[(2-hydroxyethyl)amino]-3-methoxy-2,6-dimethyl-4-[(2r)-2-methylbutanoyl]cyclohexa-2,4-dien-1-one
(1s,5s,8r,9s,11r,13r,14r,16s,17r,18s)-13-hydroxy-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecan-19-one
4,15-dimethoxy-10-methyl-10-azatetracyclo[7.7.1.0²,⁷.0¹³,¹⁷]heptadeca-1(16),2(7),3,5,13(17),14-hexaen-3-ol
C19H21NO3 (311.15213560000007)
16-hydroxy-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecan-19-one
1-methyl-2-(5-undecenyl)-4(1h)-quinolinone
{"Ingredient_id": "HBIN002732","Ingredient_name": "1-methyl-2-(5-undecenyl)-4(1h)-quinolinone","Alias": "NA","Ingredient_formula": "C21H29NO","Ingredient_Smile": "NA","Ingredient_weight": "311.466","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "NA","TCMSP_id": "NA","TCM_ID_id": "9165","PubChem_id": "NA","DrugBank_id": "NA"}
1-methyl-2-(6-undecenyl)-4(1h)-quinolinone
{"Ingredient_id": "HBIN002735","Ingredient_name": "1-methyl-2-(6-undecenyl)-4(1h)-quinolinone","Alias": "NA","Ingredient_formula": "C21H29NO","Ingredient_Smile": "NA","Ingredient_weight": "311.466","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "NA","TCMSP_id": "NA","TCM_ID_id": "9162","PubChem_id": "NA","DrugBank_id": "NA"}
2,2-dimethyl-8-[(3-methylbut-2-en-1-yl)oxy]pyrano[3,2-c]quinolin-5-ol
C19H21NO3 (311.15213560000007)
(5r,12bs)-10-methoxy-5-methyl-7,8,12b,13-tetrahydro-5h-6-azatetraphene-4,11-diol
C19H21NO3 (311.15213560000007)
(9s)-3,15-dimethoxy-10-methyl-10-azatetracyclo[7.7.1.0²,⁷.0¹³,¹⁷]heptadeca-1(16),2(7),3,5,13(17),14-hexaen-16-ol
C19H21NO3 (311.15213560000007)
(9r)-15,16-dimethoxy-10-methyl-10-azatetracyclo[7.7.1.0²,⁷.0¹³,¹⁷]heptadeca-1(16),2,4,6,13(17),14-hexaen-4-ol
C19H21NO3 (311.15213560000007)
6,13-dimethyl-7-azapentacyclo[10.8.0.0²,⁹.0⁵,⁹.0¹³,¹⁸]icosa-14,17-dien-16-one
(4s,7r)-n-[(1s)-1-hydroxyethyl]-6-methyl-6,11-diazatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-1(16),2,9,12,14-pentaene-4-carboximidic acid
(1s,5r,8r,9s,10r,11s,14s,16s,17r,18r)-10-hydroxy-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecan-19-one
3-{[2-(2-methylbut-3-en-2-yl)-1h-indol-3-yl]methyl}-3,6-dihydropyrazine-2,5-diol
(1s,20s)-20-methoxy-5,7-dioxa-14-azapentacyclo[12.7.0.0¹,¹⁷.0²,¹⁰.0⁴,⁸]henicosa-2,4(8),9,16,18-pentaene
C19H21NO3 (311.15213560000007)
7-(2h-1,3-benzodioxol-5-yl)-1-(piperidin-1-yl)hepta-2,4,6-trien-1-one
C19H21NO3 (311.15213560000007)
10-methoxy-5-methyl-7,8,12b,13-tetrahydro-5h-6-azatetraphene-2,11-diol
C19H21NO3 (311.15213560000007)
3-(12-carboxy-1-hydroxydodecyl)-2-isocyano-2-methyloxirane
1-methyl-3,3-bis(3-methylbut-2-en-1-yl)quinoline-2,4-dione
(4r,7r)-n-(1-hydroxyethyl)-6-methyl-6,11-diazatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-1(16),2,9,12,14-pentaene-4-carboximidic acid
(4r,6r,10s)-15-hydroxy-6-isopropyl-10-methyl-5-oxa-16-azapentacyclo[8.6.1.0²,⁷.0⁴,⁶.0¹⁴,¹⁷]heptadeca-1,7,14(17),15-tetraen-3-one
C19H21NO3 (311.15213560000007)
(1r,5s,13s)-10,14-dimethoxy-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0¹,¹³.0⁵,¹⁷.0⁷,¹⁸]octadeca-7,9,11(18),14,16-pentaene
C19H21NO3 (311.15213560000007)
(5s,7r,7ar)-2-(2,4-dihydroxybutyl)-3-imino-5-(2-methylprop-1-en-1-yl)-tetrahydro-1h-pyrrolo[1,2-c]imidazole-7-carboxylic acid
6-hydroxy-4,5,6-trimethyl-2,8-dioxa-13-azatricyclo[8.5.1.0¹³,¹⁶]hexadecane-3,7-dione
10,11-dimethoxy-7,8,12b,13-tetrahydro-5h-6-azatetraphen-2-ol
C19H21NO3 (311.15213560000007)
4,16-dimethoxy-10-methyl-10-azatetracyclo[7.7.1.0²,⁷.0¹³,¹⁷]heptadeca-1(16),2,4,6,13(17),14-hexaen-3-ol
C19H21NO3 (311.15213560000007)
2-[(1s,2e)-1-hydroxy-3,7-dimethylocta-2,6-dien-1-yl]-1-methylquinolin-4-one
(2r,3r)-3-[(1r)-12-carboxy-1-hydroxydodecyl]-2-isocyano-2-methyloxirane
4,9-dimethyl-6-(6-methylhept-5-en-2-yl)-6h,7h,8h,9h-naphtho[2,1-d][1,3]oxazole
4,15-dimethoxy-10-methyl-10-azatetracyclo[7.7.1.0²,⁷.0¹³,¹⁷]heptadeca-1(16),2,4,6,13(17),14-hexaen-16-ol
C19H21NO3 (311.15213560000007)
2-[(1e)-3-hydroxy-3,7-dimethylocta-1,6-dien-1-yl]-1-methylquinolin-4-one
2-[(2-hydroxyethyl)amino]-4-methoxy-1,5-dimethyl-6-oxocyclohexa-2,4-dien-1-yl 2-methylbutanoate
10-hydroxy-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecan-19-one
[(1s,7s,7as)-7-hydroxy-hexahydro-1h-pyrrolizin-1-yl]methyl 3-methyl-2-(propanoyloxy)but-2-enoate
(3e,5e,7e,11e,13z,15e,17e)-19-methyl-1-azacycloicosa-1,3,5,7,11,13,15,17-octaene-2,10-diol
10,14-dimethoxy-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0¹,¹³.0⁵,¹⁷.0⁷,¹⁸]octadeca-7,9,11(18),14,16-pentaene
C19H21NO3 (311.15213560000007)
15,16-dimethoxy-10-methyl-10-azatetracyclo[7.7.1.0²,⁷.0¹³,¹⁷]heptadeca-1(16),2,4,6,13(17),14-hexaen-14-ol
C19H21NO3 (311.15213560000007)
(2s,3s)-2-[(2e)-but-2-en-2-yl]-3-(hydroxymethyl)-3-methyl-7-phenyl-2h-furo[3,2-c]pyridin-4-ol
C19H21NO3 (311.15213560000007)
5,15-dimethoxy-10-methyl-10-azatetracyclo[7.7.1.0²,⁷.0¹³,¹⁷]heptadeca-1(16),2,4,6,13(17),14-hexaen-16-ol
C19H21NO3 (311.15213560000007)
(2e)-3-(4-hydroxyphenyl)-n-[2-(4-methoxyphenyl)ethyl]-n-methylprop-2-enamide
C19H21NO3 (311.15213560000007)
(9r)-3,15-dimethoxy-10-methyl-10-azatetracyclo[7.7.1.0²,⁷.0¹³,¹⁷]heptadeca-1(16),2(7),3,5,13(17),14-hexaen-16-ol
C19H21NO3 (311.15213560000007)
(1s)-2-[(2-hydroxyethyl)amino]-4-methoxy-1,5-dimethyl-6-oxocyclohexa-2,4-dien-1-yl (2r)-2-methylbutanoate
(5r,12bs)-10-methoxy-5-methyl-7,8,12b,13-tetrahydro-5h-6-azatetraphene-2,11-diol
C19H21NO3 (311.15213560000007)
3-(4-hydroxyphenyl)-n-[2-(4-methoxyphenyl)ethyl]-n-methylprop-2-enamide
C19H21NO3 (311.15213560000007)
(9r)-4,15-dimethoxy-10-methyl-10-azatetracyclo[7.7.1.0²,⁷.0¹³,¹⁷]heptadeca-1(16),2(7),3,5,13(17),14-hexaen-3-ol
C19H21NO3 (311.15213560000007)
n-[(3s)-2-oxooxolan-3-yl]tetradecanimidic acid
C18H33NO3 (311.24603079999997)
10',11'-dimethoxy-5'-methyl-5'-azaspiro[cyclohexane-1,2'-tricyclo[6.3.1.0⁴,¹²]dodecane]-1'(11'),2,5,8'(12'),9'-pentaen-4-one
C19H21NO3 (311.15213560000007)
(6r)-6-hydroxy-5-[(2-hydroxyethyl)amino]-3-methoxy-2,6-dimethyl-4-[(2r)-2-methylbutanoyl]cyclohexa-2,4-dien-1-one
(9r)-14,15-dimethoxy-10-methyl-10-azatetracyclo[7.7.1.0²,⁷.0¹³,¹⁷]heptadeca-1(17),2,4,6,13,15-hexaen-16-ol
C19H21NO3 (311.15213560000007)
(1s,5r,8r,9s,11r,14s,16r,17r,18r)-16-hydroxy-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecan-19-one
20-methoxy-5,7-dioxa-14-azapentacyclo[12.7.0.0¹,¹⁷.0²,¹⁰.0⁴,⁸]henicosa-2,4(8),9,16,18-pentaene
C19H21NO3 (311.15213560000007)
14,15,16-trimethoxy-10-azatetracyclo[7.7.1.0²,⁷.0¹³,¹⁷]heptadeca-1(17),2,4,6,13,15-hexaene
C19H21NO3 (311.15213560000007)
(2r)-2-[(3z)-hex-3-en-1-yl]-8-methoxy-1h,2h,3h,4h-pyrido[1,2-a]quinolin-6-one
(9s)-14,16-dimethoxy-10-methyl-10-azatetracyclo[7.7.1.0²,⁷.0¹³,¹⁷]heptadeca-1(16),2,4,6,13(17),14-hexaen-15-ol
C19H21NO3 (311.15213560000007)
(1r,4s,5s,6s,10r,16r)-5-hydroxy-4,5,6-trimethyl-2,8-dioxa-13-azatricyclo[8.5.1.0¹³,¹⁶]hexadecane-3,7-dione
2-(hex-3-en-1-yl)-8-methoxy-1h,2h,3h,4h-pyrido[1,2-a]quinolin-6-one
(12br)-10,11-dimethoxy-7,8,12b,13-tetrahydro-5h-6-azatetraphen-4-ol
C19H21NO3 (311.15213560000007)
10,11-dimethoxy-7,8,12b,13-tetrahydro-5h-6-azatetraphen-4-ol
C19H21NO3 (311.15213560000007)
6-hydroxy-5-[(2-hydroxyethyl)amino]-3-methoxy-2,6-dimethyl-4-(2-methylbutanoyl)cyclohexa-2,4-dien-1-one
6-hydroxy-8-methyl-7-(propanoyloxy)-8-azabicyclo[3.2.1]octan-3-yl (2e)-2-methylbut-2-enoate
(9s)-14,15,16-trimethoxy-10-azatetracyclo[7.7.1.0²,⁷.0¹³,¹⁷]heptadeca-1(17),2,4,6,13,15-hexaene
C19H21NO3 (311.15213560000007)
(1r,2s,5s,6s,9r,12s,13r)-6,13-dimethyl-7-azapentacyclo[10.8.0.0²,⁹.0⁵,⁹.0¹³,¹⁸]icosa-14,17-dien-16-one
2-(1-hydroxy-3,7-dimethylocta-2,6-dien-1-yl)-1-methylquinolin-4-one
2-[3-(2-hexylcyclopropyl)propyl]-1h-quinolin-4-one
1-ethyl 3-(7-hydroxy-hexahydro-1h-pyrrolizin-1-yl)methyl 2-(propan-2-ylidene)propanedioate
14,16-dimethoxy-10-methyl-10-azatetracyclo[7.7.1.0²,⁷.0¹³,¹⁷]heptadeca-1(16),2,4,6,13(17),14-hexaen-15-ol
C19H21NO3 (311.15213560000007)
1-isocyano-1,6-dimethyl-4-[6-(prop-1-en-2-yl)-5,6-dihydro-2h-pyran-3-yl]-3,4,4a,7,8,8a-hexahydro-2h-naphthalene
(1r,2s,5s,6s,9r,11s)-2-isopropyl-5-isothiocyanato-5,9-dimethyl-10,12-dioxatricyclo[7.2.1.0¹,⁶]dodecan-11-ol
C16H25NO3S (311.15550600000006)
(9r)-4,15-dimethoxy-10-methyl-10-azatetracyclo[7.7.1.0²,⁷.0¹³,¹⁷]heptadeca-1(16),2,4,6,13(17),14-hexaen-16-ol
C19H21NO3 (311.15213560000007)
5-[(4-methoxyphenyl)methyl]-6-methyl-2h,5h,7h,8h-[1,3]dioxolo[4,5-g]isoquinoline
C19H21NO3 (311.15213560000007)
(2e)-n-[(2s)-2-methoxy-2-(4-methoxyphenyl)ethyl]-3-phenylprop-2-enimidic acid
C19H21NO3 (311.15213560000007)
(2s)-2-[(3z)-hex-3-en-1-yl]-8-methoxy-1h,2h,3h,4h-pyrido[1,2-a]quinolin-6-one
(9s)-4,16-dimethoxy-10-methyl-10-azatetracyclo[7.7.1.0²,⁷.0¹³,¹⁷]heptadeca-1(16),2,4,6,13(17),14-hexaen-3-ol
C19H21NO3 (311.15213560000007)
(7-hydroxy-hexahydro-1h-pyrrolizin-1-yl)methyl 3-methyl-2-(propanoyloxy)but-2-enoate
2-(but-2-en-2-yl)-3-(hydroxymethyl)-3-methyl-7-phenyl-2h-furo[3,2-c]pyridin-4-ol
C19H21NO3 (311.15213560000007)
(1s,2s,5s,6s,8r,9r,11r)-2-isopropyl-5-isothiocyanato-5,9-dimethyl-10-oxatricyclo[6.2.1.0¹,⁶]undecane-9,11-diol
C16H25NO3S (311.15550600000006)
(9r)-14,15,16-trimethoxy-10-azatetracyclo[7.7.1.0²,⁷.0¹³,¹⁷]heptadeca-1(17),2,4,6,13,15-hexaene
C19H21NO3 (311.15213560000007)
(4r,7r)-n-[(1s)-1-hydroxyethyl]-6-methyl-6,11-diazatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-1(16),2,9,12,14-pentaene-4-carboximidic acid
(1s,4s,4as,8as)-1,6-dimethyl-4-[(6s)-6-(prop-1-en-2-yl)-5,6-dihydro-2h-pyran-3-yl]-3,4,4a,7,8,8a-hexahydro-2h-naphthalene-1-carbonitrile
(6r,9s)-4,9-dimethyl-6-[(2s)-6-methylhept-5-en-2-yl]-6h,7h,8h,9h-naphtho[2,1-d][1,3]oxazole
(6s)-6-hydroxy-5-[(2-hydroxyethyl)amino]-3-methoxy-2,6-dimethyl-4-[(2s)-2-methylbutanoyl]cyclohexa-2,4-dien-1-one
1-[(1r,2r,3as,4s,7s,7as)-1,7a-dihydroxy-7-isopropyl-4-isothiocyanato-4-methyl-hexahydro-1h-inden-2-yl]ethanone
C16H25NO3S (311.15550600000006)
1,6-dimethyl-4-[6-(prop-1-en-2-yl)-5,6-dihydro-2h-pyran-3-yl]-3,4,4a,7,8,8a-hexahydro-2h-naphthalene-1-carbonitrile
(8s,10s)-8-(2-hydroperoxypropan-2-yl)-5h,7h,8h,9h,10h-cyclohexa[b]carbazol-10-ol
C19H21NO3 (311.15213560000007)
10-methoxy-5-methyl-7,8,12b,13-tetrahydro-5h-6-azatetraphene-4,11-diol
C19H21NO3 (311.15213560000007)
5-hydroxy-4,5,6-trimethyl-2,8-dioxa-13-azatricyclo[8.5.1.0¹³,¹⁶]hexadecane-3,7-dione
(9r)-15,16-dimethoxy-10-methyl-10-azatetracyclo[7.7.1.0²,⁷.0¹³,¹⁷]heptadeca-1(16),2,4,6,13(17),14-hexaen-14-ol
C19H21NO3 (311.15213560000007)
6,13-dimethyl-7-azapentacyclo[10.8.0.0²,⁹.0⁵,⁹.0¹³,¹⁸]icosa-17,19-dien-16-one
2-(3-hydroxy-3,7-dimethylocta-1,6-dien-1-yl)-1-methylquinolin-4-one
14,15-dimethoxy-10-methyl-10-azatetracyclo[7.7.1.0²,⁷.0¹³,¹⁷]heptadeca-1(17),2,4,6,13,15-hexaen-16-ol
C19H21NO3 (311.15213560000007)
(3s)-3-{[2-(2-methylbut-3-en-2-yl)-1h-indol-3-yl]methyl}-3,6-dihydropyrazine-2,5-diol
n-[2-methoxy-2-(4-methoxyphenyl)ethyl]-3-phenylprop-2-enimidic acid
C19H21NO3 (311.15213560000007)
(5s)-5-[(4-methoxyphenyl)methyl]-6-methyl-2h,5h,7h,8h-[1,3]dioxolo[4,5-g]isoquinoline
C19H21NO3 (311.15213560000007)
(9s)-4,15-dimethoxy-10-methyl-10-azatetracyclo[7.7.1.0²,⁷.0¹³,¹⁷]heptadeca-1(16),2,4,6,13(17),14-hexaen-16-ol
C19H21NO3 (311.15213560000007)
(9s)-5,15-dimethoxy-10-methyl-10-azatetracyclo[7.7.1.0²,⁷.0¹³,¹⁷]heptadeca-1(16),2,4,6,13(17),14-hexaen-16-ol
C19H21NO3 (311.15213560000007)
2,11-dimethoxy-7,8,12b,13-tetrahydro-5h-6-azatetraphen-4-ol
C19H21NO3 (311.15213560000007)
(1r,2s,5s,6s,9r,12s,13r)-6,13-dimethyl-7-azapentacyclo[10.8.0.0²,⁹.0⁵,⁹.0¹³,¹⁸]icosa-7,17-dien-16-one
(9s)-15,16-dimethoxy-10-methyl-10-azatetracyclo[7.7.1.0²,⁷.0¹³,¹⁷]heptadeca-1(16),2,4,6,13(17),14-hexaen-4-ol
C19H21NO3 (311.15213560000007)
11,11,15-trimethyl-10,19-dioxa-2-azapentacyclo[14.2.1.0³,⁸.0⁹,¹⁸.0¹²,¹⁷]nonadeca-1,3,5,7,9(18)-pentaen-15-ol
C19H21NO3 (311.15213560000007)
2-isopropyl-5-isothiocyanato-5,9-dimethyl-10-oxatricyclo[6.2.1.0¹,⁶]undecane-9,11-diol
C16H25NO3S (311.15550600000006)
8-hydroperoxy-8-isopropyl-5-isothiocyanato-2,5-dimethyl-4,4a,6,7-tetrahydro-3h-naphthalen-2-ol
C16H25NO3S (311.15550600000006)
1-(1,7a-dihydroxy-7-isopropyl-4-isothiocyanato-4-methyl-hexahydro-1h-inden-2-yl)ethanone
C16H25NO3S (311.15550600000006)
5-ethyl-4,5-dihydroxy-1-methyl-3-(2-methylnonanoyl)pyrrol-2-one
n-{2-[4-(3-oxobutoxy)phenyl]ethyl}benzenecarboximidic acid
C19H21NO3 (311.15213560000007)
2-(but-2-en-2-yl)-3-(hydroxymethyl)-3-methyl-5-phenyl-2h-furo[2,3-b]pyridin-4-ol
C19H21NO3 (311.15213560000007)
(2s,3s)-3-[(1s)-12-carboxy-1-hydroxydodecyl]-2-isocyano-2-methyloxirane
2-isopropyl-5-isothiocyanato-5,9-dimethyl-10,12-dioxatricyclo[7.2.1.0¹,⁶]dodecan-11-ol
C16H25NO3S (311.15550600000006)
(8ar)-6,8a-diisopropyl-2,2,4-trimethyl-8h,9h-cyclopenta[g]quinolin-7-one
(10r,19s)-10-hydroxy-19-methyl-1-azacycloicosa-3,5,7,11,13,15,17-heptaen-2-one
n-(2-oxooxolan-3-yl)tetradecanimidic acid
C18H33NO3 (311.24603079999997)
2-[(1e,3r)-3-hydroxy-3,7-dimethylocta-1,6-dien-1-yl]-1-methylquinolin-4-one
(2r,3s)-2-[(2e)-but-2-en-2-yl]-3-(hydroxymethyl)-3-methyl-5-phenyl-2h-furo[2,3-b]pyridin-4-ol
C19H21NO3 (311.15213560000007)
2-[(3z)-hex-3-en-1-yl]-8-methoxy-1h,2h,3h,4h-pyrido[1,2-a]quinolin-6-one
(2r,3r)-2-[(2e)-but-2-en-2-yl]-3-(hydroxymethyl)-3-methyl-7-phenyl-2h-furo[3,2-c]pyridin-4-ol
C19H21NO3 (311.15213560000007)
